NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

Newgen Software Technologies Posts Resilient Revenue Growth Despite Macro Headwinds

Newgen Software Technologies has reported a resilient revenue growth of 5.3% year-over-year (YoY) in Q4FY26, despite facing macro headwinds in its EMEA region, which accounted for 30% of the company's revenue during the quarter. The EMEA region experienced a decline of 12.3% YoY, however this was offset by robust growth from the APAC/India region.

Notably, the company's business segments have seen significant growth, with healthcare and insurance growing by a notable 43% YoY. Additionally, Newgen has achieved gross margin expansion of 477bps YoY, which was aided by AI-led delivery gains. The company has also seen a 24% YoY expansion in subscription-based revenue, providing a stable source of income.

Key Growth Drivers

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

  • Healthcare and insurance segment grew 43% YoY
  • Gross margin expansion of 477bps YoY
  • 24% YoY expansion in subscription-based revenue
  • Strong deal pipeline with a significant uptick in deferred revenue
  • Continued strong R&D focus, representing 8.5% of revenue
SegmentQ4FY26 Growth RateQ4FY25 Growth Rate
Healthcare and Insurance43%-
Subscription-based Revenue24%-
EMEA Region-12.3%-

Newgen Software Technologies has also seen an increase in the share of annuity revenue from 56% in FY25 to 62% in FY26, with the potential to reach 75-80% in the medium term.

Outlook and Recommendations

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

We have reduced the one-year forward target price-to-earnings (P/E) ratio to 19x, as the company missed its benchmark growth of 20% YoY. We maintain a HOLD recommendation with a target price of INR 530 for March 2027, based on growth recovery estimates for FY27E (10.3%) led by a bounce-back in license revenue.

Investor Takeaway

Maintain HOLD with a Mar'27E TP of INR 530, based on growth recovery estimates.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.